Evidence map›Paper›PMID 34245210›Full record

ArticlePediatric blood & cancer2021

Prognostic value of baseline metabolic tumor volume in children and adolescents with intermediate-risk Hodgkin lymphoma treated with chemo-radiation therapy: FDG-PET parameter analysis in a subgroup from COG AHOD0031.

Sarah A Milgrom, Jihyun Kim, Alin Chirindel, Jongho Kim, Qinglin Pei, Lu Chen, Allen Buxton, Sandy Kessel, Jeffrey Leal, Kathleen M McCarten and 6 more

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Pediatric blood & cancer, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed, 1 pooled it
2.4field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 1 synthesis or guideline pooled it, 22 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Baseline and interimCancer imaging : the official publication of the International Cancer Imaging Society · 2026
    Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Observational
  9. Clinical Perspectives forMetabolites · 2022
    Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

16 authors at 11 institutions in 2 countries.

Sarah A MilgromDepartment of Radiation Oncology, University of Colorado, Aurora, Colorado, USA.ORCID 0000-0003-0037-6967
Jihyun KimDepartment of Radiology, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin, USA.
Alin ChirindelRussell H. Morgan Department of Radiology and Radiological Sciences, Johns Hopkins University, Baltimore, Maryland, USA.
Jongho KimRussell H. Morgan Department of Radiology and Radiological Sciences, Johns Hopkins University, Baltimore, Maryland, USA.
Qinglin PeiChildren's Oncology Group, Statistics and Data Center, Department of Biostatistics, University of Florida, Gainesville, Florida, USA.
Lu ChenChildren's Oncology Group, Statistics and Data Center, Department of Biostatistics, University of Florida, Gainesville, Florida, USA.
Allen BuxtonChildren's Oncology Group, Statistics and Data Center, Monrovia, California, USA.
Sandy KesselImaging and Radiation Oncology Core Group, Lincoln, Rhode Island, USA.
Jeffrey LealRussell H. Morgan Department of Radiology and Radiological Sciences, Johns Hopkins University, Baltimore, Maryland, USA.
Kathleen M McCartenImaging and Radiation Oncology Core Group, Lincoln, Rhode Island, USA.
Bradford S HoppeDepartment of Radiation Oncology, Mayo Clinic, Jacksonville, Florida, USA.ORCID 0000-0002-2312-5418
Suzanne L WoldenDepartment of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, New York, USA.ORCID 0000-0002-5234-4134
Cindy L SchwartzDivision of Pediatric Hematology, Oncology, and BMT, Medical College of Wisconsin, Milwaukee, Wisconsin, USA.
Debra L FriedmanDivision of Pediatric Hematology and Oncology, Vanderbilt University Medical Center, Nashville, Tennessee, USA.
Kara M KellyDepartment of Pediatric Oncology, Roswell Park Comprehensive Cancer Center, and University at Buffalo Jacobs School of Medicine and Biomedical Sciences, Buffalo, New York, USA.
Steve Y ChoDepartment of Radiology, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin, USA.
University of Wisconsin–Madison · USCalista Therapeutics (United States) · USJohns Hopkins University · USUniversity of Florida · USChildren's Oncology Group · USJacksonville College · USMedical College of Wisconsin · USMemorial Sloan Kettering Cancer Center · USRoswell Park Comprehensive Cancer Center · USUniversity of Colorado Anschutz Medical Campus · USVanderbilt University · US

Funding

NCTN BIQSFP ANBL1531 (NRT)U10CA180886 · NCI · PUBLIC HEALTH INSTITUTE · PI Douglas S. Hawkins · 2014 to 2026
$390.6M
X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Hongbiao Carl Lekaye · 1985 to 2026
$347.4M
COG SDMC - Statistics CoreU10CA180899 · NCI · UNIVERSITY OF SOUTHERN CALIFORNIA · PI TODD A ALONZO · 2014 to 2026
$132.8M
NCI NIH HHS P30 CA008748NCI NIH HHS U10 CA180886NCI NIH HHS U10 CA180899
6 · The paper itself

Abstract

backgroundPositron emission tomography (PET)-based measures of baseline total-body tumor burden may improve risk stratification in intermediate-risk Hodgkin lymphoma (HL). MATERIALS AND

methodsEvaluable patients were identified from a cohort treated homogeneously with the same combined modality regimen on the Children's Oncology Group AHOD0031 study. Eligible patients had high-quality baseline PET scans. Metabolic tumor volume (MTV) and total lesion glycolysis (TLG) were each measured based on 15 thresholds for every patient. Univariate and multivariable Cox regression and Kaplan-Meier survival analyses assessed for an association of MTV and TLG with event-free survival (EFS).

resultsFrom the AHOD0031 cohort (n = 1712), 86 patients were identified who (i) were treated with four cycles of doxorubicin, bleomycin, vincristine, etoposide, prednisone, cyclophosphamide (ABVE-PC) chemotherapy followed by involved field radiotherapy, and (ii) had a baseline PET scan that was amenable to quantitative analysis. Based on univariate Cox regression analysis, six PET-derived parameters were significantly associated with EFS. For each of these, Kaplan-Meier analyses and the log-rank test were used to compare patients with highest tumor burden (i.e., highest 15%) to the remainder of the cohort. EFS was significantly associated with all six PET parameters (all p < .029). In a multivariable model controlling for important covariates including disease bulk and response to chemotherapy, MTV

conclusionMultiple baseline PET-derived volumetric parameters were associated with EFS. MTV

Indexed as

Fluorodeoxyglucose F18Hodgkin DiseaseAdolescentChildHumansPositron-Emission TomographyPrognosisRadiopharmaceuticalsRetrospective StudiesTumor BurdenFluorodeoxyglucose F18RadiopharmaceuticalsAHOD0031Hodgkinlymphomametabolic tumor volumeMTVPETpositron emission tomography

Identifiers

PMID34245210
PMCPMC8809108
OpenAlexW3181054131

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.